Evidence map›Paper›PMID 39052703›Full record

ArticleThe Journal of infectious diseases2024

Prevotella timonensis Bacteria Associated With Vaginal Dysbiosis Enhance Human Immunodeficiency Virus Type 1 Susceptibility Of Vaginal CD4+ T Cells.

Nienke H van Teijlingen, Marleen Y van Smoorenburg, Ramin Sarrami-Forooshani, Esther M Zijlstra-Willems, John L van Hamme, Hanneke Borgdorff, Janneke H H M van de Wijgert, Elisabeth van Leeuwen, Joris A M van der Post, Karin Strijbis and 2 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nienke H van TeijlingenDepartment of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5693-1619
Marleen Y van SmoorenburgDepartment of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-2413-0136
Ramin Sarrami-ForooshaniDepartment of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-6999-9145
Esther M Zijlstra-WillemsDepartment of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
John L van HammeDepartment of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0765-9441
Hanneke BorgdorffAmsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.ORCID 0000-0003-4277-9377
Janneke H H M van de WijgertJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-2728-4560
Elisabeth van LeeuwenDepartment of Obstetrics and Gynecology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-2463-9127
Joris A M van der PostDepartment of Obstetrics and Gynecology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-3311-2116
Karin StrijbisDepartment of Biomolecular Health Sciences, Division of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0001-9167-7137
Carla M S RibeiroDepartment of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5682-4143
Teunis B H GeijtenbeekDepartment of Experimental Immunology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5710-2839

Funding

Dutch Research Council 91218017;European Research Council 670424
6 · The paper itself

Abstract

Dysbiosis of the vaginal microbiome poses a serious risk for sexual human immunodeficiency virus type 1 (HIV-1) transmission. Prevotella spp are abundant during vaginal dysbiosis and associated with enhanced HIV-1 susceptibility; however, underlying mechanisms remain unclear. Here, we investigated the direct effect of vaginal bacteria on HIV-1 susceptibility of vaginal CD4+ T cells. Notably, pre-exposure to Prevotella timonensis enhanced HIV-1 uptake by vaginal T cells, leading to increased viral fusion and enhanced virus production. Pre-exposure to antiretroviral inhibitors abolished P timonensis-enhanced infection. Our study shows that the vaginal microbiome directly affects mucosal CD4+ T-cell susceptibility, emphasizing importance of vaginal dysbiosis diagnosis and treatment.

Indexed as

CD4-Positive T-LymphocytesDysbiosisHIV-1HIV InfectionsPrevotellaVaginaDisease SusceptibilityFemaleHumansMicrobiotaVirus InternalizationCD4+ T cellsHIV-1 susceptibilitymicrobiomePrevotella timonensisvaginal dysbiosis

Identifiers

PMID39052703
PMCPMC11272099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.